Biotech Archives - Spark Newswire

2 minute read

Industry Groups Back GSK’s Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer

June 20, 2:03 PM

GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency.

GSK

2 minute read

Johnson & Johnson Faces New Lawsuit(s) Related To Its Talc Products

By Vandana Singh

June 20, 1:53 PM

Johnson & Johnson faces a new class action lawsuit seeking damages and medical monitoring for cancer risk from talc products.

JNJ

2 minute read

German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount

By Vandana Singh

June 20, 1:46 PM

Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.

BMY

2 minute read

What’s Going On With Neurological Disease Focused Trevena On Thursday?

By Vandana Singh

June 20, 12:50 PM

Trevena shares dropped 33.7% to $0.23 with a session volume of 23.65 million. Notably, TRV045 did not cause S1P1R desensitization or protein reduction, unlike fingolimod.

NVS

1 minute read

Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?

By Vandana Singh

June 20, 12:29 PM

Jazz Pharmaceuticals announced Phase 2b trial results for suvecaltamide (JZP385) in essential tremor patients, revealing no significant improvements over placebo.

JAZZ

2 minute read

PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder

By Vandana Singh

June 20, 10:09 AM

PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on PTC518 for Huntington's disease. The FDA has lifted the partial clinical hold on the program.

PTCT

2 minute read

What’s Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

By Vandana Singh

June 20, 9:43 AM

Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients using TPST-1120 combined with atezolizumab and bevacizumab.

TPST

2 minute read

EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder

By Vandana Singh

June 20, 8:00 AM

Adial Pharmaceuticals publishes Phase 3 ONWARD study results in the European Journal of Internal Medicine. The study reveals AD04 significantly reduces heavy drinking days, with adverse events matching the placebo.

ADIL

2 minute read

What Is The Trump Factor? Justice Dept’s Impact On Cannabis Rescheduling, Stocks And Investments

By Nicolas Jose Rodriguez

June 18, 5:03 PM

Equity research firm Zuanic & Associates convened a panel in mid-June featuring industry experts to dissect the ongoing cannabis rescheduling efforts in the US. They provided a comprehensive outlook on the rescheduling process, expected to conclude with the publication of the Final Rule in the Federal Register by November 2024.

CRLBF

1 minute read

Indivior Announces The Publication Of New Data On The Comparative Effectiveness Of Intranasal Nalmefene And IN Naloxone 4 mg In A Translational Model Assessing The Impact Of A Synthetic Opioid Overdose On Respiratory Depression And Cardiac Arrest In Th…

By Benzinga Newsdesk

June 18, 3:42 PM

Large reductions in the incidence of simulated cardiac arrest caused by potentially lethal doses of fentanyl or carfentanil were observed following a single IN dose of OPVEE compared to a single dose of IN

INDV